Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04198259
Other study ID # KY20192116-F-1
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 1, 2020
Est. completion date December 31, 2022

Study information

Verified date February 2020
Source Fourth Military Medical University
Contact Jun Tie, M.D.,Ph.D.
Phone +862984771537
Email tiejun7776@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Gastric varices (GV) are present in around 20% of patients with cirrhosis. Bleeding from GV accounts for 10-20% of all variceal bleeding. For the prevention of gastric variceal bleeding, TIPS or BRTO as firstline treatments were suggested.

No randomized trials have compared BRTO with other therapies. BRTO and its variations might increase portal pressure and might worsen complications, such as ascites or bleeding from EV. In this regard, if NSBB is combined with BRTO and its variations (we called interventional devascularization) for those HVPG responders, the drawbacks of interventional devascularization might be overcome. Therefore, the investigators conducted this RCT to compare the effectiveness and safety of TIPS with those of interventional devascularization in the prevention of rebleeding from gastric varices.


Description:

Gastric varices (GV) are present in around 20% of patients with cirrhosis. Bleeding from GV accounts for 10-20% of all variceal bleeding. GV are classified according to their location in the stomach and their relationship with esophageal varices (EV). Accordingly, GV are divided into gastroesophageal varices (GOV) and isolated gastric varices (IGV) . The management of type 1 GOV, which extend from the esophagus along the lesser curvature of the stomach, is similar to the management of EV. Historically, bleeding from type 2 GOV (i.e. GOV extending into the fundus), type 1 IGV (i.e. located in the fundus) and type 2 IGV (i.e. located anywhere in the stomach), is considered to be more severe and difficult to treat than EV bleeding. Few studies, mostly retrospective and uncontrolled, have focused on the management of non-GOV1 GV, and the optimal treatment remains controversial.

For the prevention of gastric variceal bleeding, treatment principles can be classified into two categories: decreasing portal pressure and obstructing GEV. Methods for decreasing portal pressure include medications (NSBB), radiological intervention (TIPS) and surgery. In contrast, methods for treating the obstruction of GEV include endoscopic approaches (EVL, EIS) or radiological intervention (such as BRTO). Recent portal hypertensive bleeding suggested TIPS or BRTO as firstline treatments in the prevention of rebleeding.

BRTO is a procedure for treatment of fundal varices associated with a large gastro-/splenorenal collateral. The technique involves retrograde cannulation of the left renal vein by the jugular or femoral vein, followed by balloon occlusion and slow infusion of sclerosant to obliterate the gastro-/splenorenal collateral and fundal varices. Several variations of the technique exist, such as balloon-occluded antegrade transvenous obliteration or occlusion of the collateral by the placement of a vascular plug or coils. BRTO has the theoretical advantage over TIPS that it does not divert portal blood inflow from the liver. On the other hand, BRTO and its variations might increase portal pressure and might worsen complications, such as ascites or bleeding from EV. In this regard, if NSBB is combined with BRTO and its variations (we called interventional devascularization) for those HVPG responders, the drawbacks of interventional devascularization might be overcome.

Therefore, the investigators conducted this RCT to compare the effectiveness and safety of TIPS with those of interventional devascularization in the prevention of rebleeding from gastric varices.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 212
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Liver cirrhosis diagnosed by clinical examination, imaging or biopsy

- Patients with a previous history of variceal hemorrhage

- Gastric variceal confirmed by an endoscopic examination, including IGV1 or IGV2

- Aged 18 to 75 years

- Adequate liver and kidney function, including Child-Turcotte-Pugh score < 12, MELD score <19, and serum creatinine less than 2 times the upper limit of normal.

Exclusion Criteria:

- Active variceal bleeding

- Esophageal variceal, including GOV1 or GOV2 type, mainly esophageal varices;

- Refractory ascites

- Patients with contraindication to treatment of TIPS, including congestive heart failure, NYHA III and IV, pulmonary arterial hypertension(>50mmHg), polycystic liver, intrahepatic duct dilatation, spontaneous bacterial peritonitis, hepatic encephalopathy

- Patients with contraindication to treatment of Carvedilol, including asthma, insulin-dependent diabetes, peripheral vascular diseases

- Child-Turcotte-Pugh score >=12, or MELD score >=19

- Budd-Chiari syndrome

- The main portal vein thrombosis is greater than 50%

- Malignancies

- An uncontrolled infection

- Previously treated with TIPS, splenectomy pericardia vascular disconnection, or surgical shunts

- HIV or HIV related illness

- Allergic to contrast agent

- Lactating or pregnant

- Non-compliant patients

Study Design


Intervention

Procedure:
interventional devascularization
Interventional devascularization (BRTO and its variations) is a procedure for treatment of fundal varices associated with a large gastro-/splenorenal collateral.
TIPS
TIPS is very effective in the treatment of bleeding GV, with more than a 90% success rate for initial hemostasis. It frequently requires additional embolization of spontaneous collaterals feeding the varices. The incidence of encephalopathy was higher after TIPS.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Fourth Military Medical University

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative incidence of gastric variceal rebleeding Confirmed by endoscopy 12 months
Secondary Cumulative incidence of variceal hemorrhage related death 12 months
Secondary Cumulative incidence of hepatic encephalopathy (HE) HE is classified as covert HE and overt HE 12 months
Secondary Cumulative incidence of death all cause mortality 12 months
Secondary Cumulative incidence of adverse events number of adverse events and adverse reactions in each arm 12 months
Secondary Correlation between hepatic venous pressure gradient response and cardiac index response to Carvedilol Investigate non-invasive tools for risk stratification 12 months
See also
  Status Clinical Trial Phase
Terminated NCT03219372 - Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence Phase 2
Recruiting NCT03624517 - Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices Phase 4
Recruiting NCT04057287 - Risk Factors of Liver Fibrosis Among First Degree Relatives of Patients With NASH Related Cirrhosis (NRC)
Recruiting NCT04089878 - "To Study the Impact of Balloon-occluded Retrograde Transvenous Obliteration (BRTO)/Plug Assisted Retrograde Transvenous Obliteration (PARTO) Mediated Portal Flow Modulation in Reduction of Ammonia and Improvement in Organ Volume and Functionality in Patients of Cirrhosis With LR Shunt N/A
Completed NCT04212286 - Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC N/A
Completed NCT04474743 - Malnutrition in Chronic Gastrointestinal Diseases, Cross-sectional Study
Recruiting NCT03694691 - Developing Viability Index for Machine Perfused Livers N/A
Terminated NCT04072601 - Statins for Prevention of Disease Progression and Hospitalization in Liver Cirrhosis Phase 4
Terminated NCT03878563 - Alterations in Intestinal Mucosal Barrier Visualized by Confocal Laser Endomicroscopy in Liver Cirrhosis: a Pilot Trial (AMBIC)
Terminated NCT04160039 - Early Cycle Ergometry for Critically-Ill Liver Failure Patients in a Transplant Intensive Care Unit N/A
Recruiting NCT04191369 - EGD vs EUS in Diagnosing Portal Hypertension in Cirrhotic Patients. N/A
Completed NCT03083925 - Viatorr CX Case-control Study for Complications of Portal Hypertension
Not yet recruiting NCT03855709 - Antibiotic-resistant Bacterial Infection of Hepatic Patients
Recruiting NCT02484573 - Evaluation of Intestinal Permeability in Cirrhotic Patients Before and After Treatment With Non-selective Beta Blocker (Propranolol) N/A
Recruiting NCT04357600 - Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B Phase 1/Phase 2
Completed NCT03156426 - Prognostic Biomarkers For Acute Kidney Injury In Liver Cirrhosis
Active, not recruiting NCT03868397 - Preoperative Portal and Splanchnic Flow Measurement Using MRI N/A
Terminated NCT03650660 - Concordance Between Echocardiographic Assessment Performed in the Initial Phase of Decompensated Cirrhosis With Edema and Ascites by an Expert Intensive Care Physician and a Non-expert Gastroenterologist
Completed NCT03871894 - Indirect Calorimeter Based Study in Patients With Liver Cirrhosis N/A
Completed NCT03283176 - Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin